NUPATHE Community Page | What other sites are saying about NUPATHE

NUPATHE

(NQ: PATH)

3.200 USD +0.050 (+1.59%)

Official Closing Price / Updated: 8:10 PM EDT, May 17, 2013 / Add to My Watchlist

(PATH) Community Analysis from

Related Wikinvest articles

May 19, 2013

BioMarin Pharmaceutical Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

(Phil’s Stock World, 8/7/12)

Courtesy of Benzinga. NuPathe Inc. (NASDAQ: PATH), today announced that it has granted time-based stock options to Armando Anido,...(read more)

NuPathe on Wrong Path to Success

(Benzinga, 8/31/11)

NuPathe announced on Tuesday that its application for FDA approval of its migraine patch Zelrix has been rejected, as the agency cited safety and manufacturing issues as the primary reasons for...(read more)

NuPathe Surges On Drug Safety Results (PATH)

(Benzinga, 10/19/10)

Shares of specialty pharmaceutical company NuPathe (NASDAQ:PATH) have climbed 16.28% to $7.00 on the back of promising top-line safety results for its migraine drug Zelrix. A total of 183 patients were enrolled in the trial, and Zelrix...(read more)

View all posts about NuPathe (PATH)

NuPathe (PATH) Company Overview

There is no analysis for PATH yet. But you can go to Wikinvest to help create one!

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates